Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
The method of treating patients be administering phenylalkyl N-hydroxurea derivatives for combating atherosclerotic plaque and cardiovascular diseases and compositions for this use.
1. A method for preventing or treating atherosclerotic plaque in human patients comprising administering to a patient a composition containing a compound of the formula:
wherein R is hydrogen, lower alkyl, halogen, trifluoromethyl, lower alkoxy or hydroxy; Y is —O— or —S—; L is lower alkylene or lower alkenylene;
X is a branched- or straight-chain lower alkylene and M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation and a pharmaceutically acceptable metabolically cleavable group selected from —COR, —COOR, —CONRR and —CH 2 OR radicals wherein R is independently selected in each occurrence from the group consisting of alkyl, trialkylsilyl, carbocyclic aryl and carbocylic aryl substituted with one or more substituents selected from the group consisting of C 1 -C 4 alkyl, halogen, hydroxy and C 1 -C 4 alkoxy;
or pharmaceutically effective salts thereof with said compound being administered in an amount effective to prevent or treat atherosclerotic plaque consisting of a daily dosage of from about 0.2 to about 3.0 mg/kg of body weight.
2. The method of claim 1 , wherein said administration is to treat patients who have been diagnosed as having atherosclerotic plaque.
3. The method of claim 2 , wherein the treatment is to stabilize or retard the formation of further atherosclerotic plaque.
4. The method of claim 3 , wherein said compound is N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea.
5. The method of claim 3 , wherein said composition is administered orally.
6. The method of claim 5 , wherein said compound is N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea.
7. The method of claim 1 , wherein said administration is to patients who have had previous heart attacks or strokes caused by atherosclerotic plaque.
8. The method of claim 7 , wherein the administration is for preventing or retarding the formation of atherosclerotic plaque.
9. The method of claim 8 , wherein said compound is N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea.
10. The method of claim 8 , wherein said composition is administered orally.
11. The method of claim 10 , wherein said compound is N-[3-[5-(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea.
12. The method of claim 1 , wherein said administration is to patients which are susceptible to cardiovascular diseases.
13. The method of claim 12 , wherein said administration is for retarding or preventing the formation of atherosclerotic plaque.
14. The method of claim 13 , wherein said compound is N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea.
15. The method of claim 13 , wherein said composition is administered orally.
16. The method of claim 15 , wherein said compound is N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea.
17. A composition in unit dosage form for oral administration comprising as an active ingredient a compound of the formula:
wherein R is hydrogen, lower alkyl, halogen, trifluoromethyl, lower alkoxy or hydroxy; Y is —O— or —S—; L is lower alkylene or lower alkenylene; X is a branched—or straight—chain lower alkylene and M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation and a pharmaceutically acceptable metabolically cleavable group selected from —COR, —COOR, —CONRR and —CH 2 OR radicals wherein R is indenendently selected in each occurrence from the group consisting of alkyl, trialkylsilyl, carbocyclic aryl and carbycyclic aryl substituted with one or more substituents selected from the group consisting of C 1 -C 4 alkyl, halogen, hvdroxy and C 1 -C 4 alkoxy;
or a pharmaceutically accepted salt thereof, said active ingredient being present in an amount selected from the group consisting of 25 mg, 50 mg and 75 mg.
18. The composition of claim 17 , wherein said active ingredient is N-[5-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea.
19. The composition of claim 18 , wherein said unit oral dosage form is a tablet or capsule.
20. The composition of claim 19 , wherein said active ingredient is N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea.